$TATATECH : Constant currency revenue grew 4.3% QoQ, with management guiding for strong double-digit organic revenue growth in FY27. $ADANIPOWER : Board to consider fundraising via QIP and other avenues at its meeting on July 22. $KERNEX : Secured two orders worth ₹250–600 crore from BWSSB, strengthening its order book. $NATCOPHARM : Received US FDA tentative approval for Olaparib tablets, expanding its oncology product pipeline. $KOLTEPATIL : Q1 sales remained flat, while collections increased 30% YoY, indicating healthy cash flow. $TURTLEMINT : Reported its first-ever quarterly profit (PAT positive) in Q1 FY27.

#StockInNews

603 likes·25 comments